Skip to main content

IAVI Portfolio

IAVI is advancing a distinct portfolio of preventive HIV vaccine candidates through its research and development programs, taking two primary approaches to design candidates: blocking HIV infection by engaging the antibody response or destroying infected cells via cell mediated immunity (CMI). Current CMI-based approaches include the development of replicating vectors and prime-boost strategies.